DFSK Celebrates 20 Years in Peru with the Launch of E5 PLUS

LIMA, Peru, Oct. 9, 2026 /PRNewswire/ -- DFSK celebrated its 20th anniversary in Peru with the official launch of the E5 PLUS, a seven-seat plug-in hybrid SUV. Held in Lima, the event brought together company representatives, local dealers, media and business partners to mark two decades of the brand's presence in Peru and introduce its next chapter.

The event also marked the introduction of DFSK's refreshed global brand direction, "DRIVES FOR BETTER," reflecting its commitment to delivering better products and services to customers.

20 Years in Peru: A New Chapter Begins

DFSK first entered the Peruvian market in 2006 with commercial vehicles. Over the following two decades, the brand expanded into passenger vehicles and, more recently, new energy vehicles, while establishing a local sales and after-sales service network.

Today, DFSK operates 27 authorized dealerships across Lima and other major cities in Peru. As part of SERES Group, DFSK continues to expand its new energy vehicle offerings in the market.

"This year marks DFSK's 20th anniversary in Peru — a milestone, but also a new beginning. DFSK understands this market, believes in its potential, and remains firmly committed to investing in its future," said Xie Mingru, DFSK Representative.

The anniversary reflects DFSK's journey from commercial vehicles to passenger vehicles and its ongoing transition toward new energy mobility, marking a new stage in the brand's development in Peru.

E5 PLUS: More Possibilities for Family Travel

The E5 PLUS combines plug-in hybrid technology, a spacious seven-seat interior and extended driving range, offering Peruvian families greater flexibility for everyday commuting and longer journeys.

Equipped with the SERES Super Hybrid system, the SUV offers an NEDC-rated all-electric driving range of up to 142 km and a combined driving range of up to 1,200 km. The combination of electric driving capability and extended range is designed to accommodate a variety of travel needs, from daily city driving to family road trips.

At the launch, guests explored the E5 PLUS through three interactive experience zones highlighting its key features.

An outdoor camping display demonstrated the vehicle's external power supply capability, powering equipment including lighting, a projector and cooking appliances.

A cargo demonstration showcased the SUV's interior space and storage versatility, while an interactive display illustrated its extended driving range and potential fuel cost savings.

The event also welcomed Milett Figueroa, who was introduced as the DFSK E5 PLUS product ambassador. She joined guests at the launch and shared her impressions of the vehicle's design, technology and comfort.

Building on Two Decades of Trust

The launch of the E5 PLUS marks another step in DFSK's development in Peru, bringing a plug-in hybrid SUV to customers seeking a combination of space, driving range and everyday practicality.

Under its "DRIVES FOR BETTER" brand direction, DFSK will continue to focus on providing reliable products and quality services, while developing new energy mobility solutions for customers in Peru.

For DFSK, the 20th anniversary is both a celebration of its history in Peru and the beginning of a new chapter. Building on its established local network and customer relationships, the brand remains committed to growing alongside Peruvian customers and delivering products and services that meet their changing needs.

SOURCE DFSK

Share this article

Boliden's Nomination Committee for the 2027 Annual General Meeting

STOCKHOLM, Oct. 9, 2026 /PRNewswire/ -- Under the instructions adopted by Boliden AB's Annual General Meeting, and subject to their willingness to participate, Boliden's Nomination Committee shall consist of members appointed by the three largest shareholders by voting rights, based on Euroclear Nordics AB's print-out of the share register as of August 31, 2026.

In accordance herewith, the Nomination Committee has now been appointed and consists of the following members:

- Lennart Francke, Swedbank Robur Fonder, Chair of the Nomination Committee

- Magnus Tell, Alecta

- Karin Eliasson, Handelsbanken Fonder

The Chair of the Board, Karl-Henrik Sundström, has been co-opted to the Nomination Committee.

Prior to the 2027 Annual General Meeting, the Nomination Committee shall prepare proposals for the Chair of the Meeting, the number of Board members, Board and committee fees, the election of Board members and the Chair of the Board, fees for the auditor and the election of the auditor, as well as any proposals for changes to the Nomination Committee's instructions.

The Annual General Meeting is scheduled to take place on April 28, 2027, at Rönnskär, Skellefteå. Shareholders who wish to submit proposals to the Nomination Committee may contact the Nomination Committee by email at [email protected]. For proposals to be considered, they must be received by the Nomination Committee no later than January 29, 2027.

Stockholm, October 9, 2026

For further information, please contact:

Daniel Isaksson Bonnevier

Head of Corporate Communications

+46 70 429 45 78

[email protected] 

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE Boliden

Share this article

Global CEOs to explore new opportunities in Shanghai

SHANGHAI, Oct. 9, 2026 /PRNewswire/ -- A news report from english.shanghai.gov.cn:

The 38th meeting of the International Business Leaders' Advisory Council for the Mayor of Shanghai will take place in Shanghai on Oct 10 and 11, bringing together business leaders from China and abroad to discuss service sector innovation and explore new opportunities for cooperation.

As Shanghai businesses look to go global, multinational companies are seeking deeper cooperation with Chinese enterprises and further opportunities in the Chinese market. Since last year's meeting, more than 20 IBLAC member companies have identified new investment projects, according to preliminary statistics.

Global expansion

A dedicated session will explore how IBLAC members can support Chinese companies expanding overseas through their international experience and service networks.

Tan Su Shan, CEO of DBS Group and an IBLAC member, said the bank's presence in China and Southeast Asia enables it to support Chinese companies going global through financial technology, regional connectivity and cross-border renminbi solutions.

Tan Limin, chairman of Shanghai-based Westwell, said his company hopes to learn from international peers about long-term strategic management, global innovation networks and cross-cultural organizational development.

AI cooperation

Artificial intelligence has become an increasingly prominent topic at IBLAC. Last year, eight Shanghai AI companies showcased robots and other technologies at an off-site event. This year's session will take participants to Fuxing Island to experience AI applications in services and other real-world settings.

AI is also a key theme in annual reports submitted by member companies on Shanghai's development. ABB recommended developing AI-powered energy systems, Novartis proposed combining family doctors with AI to manage hyperlipidemia in communities, and Royal Vopak suggested building a resilient, green marine fuel bunkering and supply system.

Zhu Jie, a partner and senior vice-president of Shanghai-based embodied AI company AgiBot, said international companies are increasingly focused on how embodied AI can improve productivity. AgiBot and IBLAC member companies have explored cooperation in industrial handling, logistics sorting, and service retail.

Shanghai solutions

At last year's meeting, Mark J. Greeven, a professor at the International Institute for Management Development, called on Shanghai to focus on system-shaping innovation. He said the key was turning scattered innovations into scalable products and industrial capabilities aligned with clear application goals.

Such an approach could offer lessons for innovation hubs worldwide, according to Greeven. IBLAC has evolved from a platform for Shanghai to learn from international peers into one for mutual exchange and the development of solutions with broader relevance. It also helps multinational companies better understand Shanghai and identify investment opportunities.

Boehringer Ingelheim Greater China plans to establish a new R&D center in Zhangjiang to strengthen early clinical development and external innovation collaboration. Vale China also hopes to connect China with Brazil and the wider Latin American region, supporting Shanghai's role in AI governance, the green energy transition, and digital infrastructure.

SOURCE english.shanghai.gov.cn

Share this article

AI Data Fusion Clean Rooms Facilitate Collaboration by Merging Sensitive or Live Data, Develop and Run Models Without Privacy Risk

PALO ALTO, Calif., Oct. 9, 2026 /PRNewswire/ -- Anjuna Security, a leader in confidential computing and autonomous software runtime governance, today announced that Anjuna Northstar has been recognized as the winner of the "Data Privacy Solution of the Year" award in the 10th annual CyberSecurity Breakthrough Awards program. Conducted by CyberSecurity Breakthrough, an independent market intelligence organization, the annual program recognizes the most innovative companies, products, and technologies driving progress in the global information security industry.

Anjuna Northstar is the industry's first AI model and data fusion clean room. Built on top of Anjuna Seaglass, the company's Universal Confidential Computing Platform, Anjuna Northstar ensures that code and data remain protected, from ingestion to processing to analysis. Designed for AI ops teams and data scientists, Anjuna Northstar lets collaboration partners share sensitive data, develop and run models, and get actionable results, all with verifiable trust and no data privacy risk. New confidential clean rooms can be created on demand, and stakeholders can collaborate using common tools such as Jupyter notebooks.

"Traditional clean rooms lack the flexibility and scalability required to meet the demands of today's data-driven, security-first enterprises," said Ayal Yogev, CEO of Anjuna Security. "We designed Anjuna Northstar to enable interactive data ops and AI-driven dataset fusion for secure, verifiable collaboration. This win with CyberSecurity Breakthrough validates our approach to liberate organizations from the constraints of data sharing. Anjuna Northstar empowers them to securely embrace the limitless potential of cloud and AI."

Using Anjuna Northstar, partners can prepare datasets interactively within a secure environment. Remote attestation and data-in-use isolation enable companies to reduce risks and guarantee the highest level of privacy and security for every collaboration. By leveraging confidential computing technology, attack vectors that are hardware-based and memory-based are closed off. The product works with any cloud provider and on-premises environments.

Marking its 10-year milestone this year, the CyberSecurity Breakthrough Awards has spent a decade on a mission that hasn't wavered: to celebrate excellence and spotlight breakthrough innovation driving the global cybersecurity industry forward. Over that decade, the program has grown to span a wide range of categories, including Cloud Security, Threat Intelligence, Risk Management, Fraud Prevention, Mobile Security, Application Security, Identity Management, and more, consistently shining a light on the solutions and organizations redefining how we safeguard the digital world.

In this landmark 10th year, the 2026 awards program received thousands of nominations from organizations in more than 20 countries around the world, representing breakthrough technologies from disruptive startups to established global enterprises. This year's winners embody the cutting edge of cybersecurity technology, delivering next-generation protection and resilience in today's increasingly complex threat landscape.

"Anjuna Northstar unlocks collaboration across industries. Enterprises want to realize the full value of their data through partnerships and collaboration while ensuring security is never compromised. AI models offer new ways to analyze, predict, and innovate, but also introduce a range of risk vectors that traditional tools, like legacy data clean rooms, were not designed to protect against," said Steve Johansson, managing director, CyberSecurity Breakthrough. "Anjuna Northstar protects diverse data sources using confidential computing so that enterprises can freely share and collaborate, uncover new insights, explore growth opportunities, and achieve innovations that were previously out of reach."

About Anjuna Security

Anjuna Security envisions a world where every enterprise can trust the autonomous software that runs the business. Anjuna's platform comprises Anjuna Seaglass for data-in-use protection and Anjuna Overwatch for agentic AI governance, providing hardware-rooted trust with cryptographic guarantees when running sensitive workloads and AI agents without application changes. Anjuna is trusted by leading financial services, defense, and healthcare organizations to meet the security and compliance demands of today's AI-driven enterprise. Learn more at anjuna.io.

About CyberSecurity Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the CyberSecurity Breakthrough Awards program is devoted to honoring excellence in information security and cybersecurity technology companies, products and people. The CyberSecurity Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough information security companies and products in categories including Cloud Security, Threat Detection, Risk Management, Fraud Prevention, Mobile Security, Web and Email Security, UTM, Firewall and more. For more information visit CyberSecurityBreakthrough.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Media Contact:

Yu-Ting Huang

Email: [email protected]

SOURCE Anjuna Security, Inc

Share this article

MIDEA COMPLETES THE ACQUISITION OF ESAOTE

Midea Group marks its commitment to healthcare and innovation by completing the acquisition of Esaote

GENOA, Italy, Oct. 9, 2026 /PRNewswire/ -- Esaote S.p.A., a leader in the medical imaging sector, announces the completion of the controlling stake acquisition of its share capital by Midea – the Chinese global technology group headquartered in the district of Shunde, Foshan.

The transaction is aimed at fostering synergies between Esaote and Midea's Healthcare Division to increase international competitiveness. Esaote will be part of Midea Healthcare and will continue to operate as an independent global medical equipment company, headquartered in Genoa, Italy, with R&D and manufacturing facilities in Italy and the Netherlands.

For Esaote, it represents a great opportunity: Midea, a highly reputed and well-established global player, with proven industrial expertise and a well-developed international network, will accelerate Esaote's growth through targeted investments in R&D, operations and manufacturing capabilities.

The new partnership will provide Esaote with enhanced access to a broader technology ecosystem, complementary imaging capabilities and a larger innovation platform. Esaote would be ideally positioned to leverage on product development, shorten innovation cycles and explore new applications and market segments.

Meanwhile, the transaction will strengthen Midea's positioning on the medical imaging business globally. Midea's comprehensive product portfolio - covering DR, high-field MRI, CT and DSA - perfectly complements Esaote's globally recognized premium brand and proven strengths in ultrasound, open and dedicated MRI systems, as well as medical IT solutions, creating robust synergies between both parties.

The company will continue to be led by Franco Fontana, who has been confirmed by the new shareholders in his role as CEO.

STATEMENT from FRANCO FONTANA, CEO of Esaote: "This transaction sets an exciting new era for Esaote. In the last years, the company has expanded its international operations and has gained increasing world-wide recognition by the clinical and the scientific communities. Empowered by Midea, one of the most successful technology group, Esaote will proudly contribute its vision and innovation to advance the healthcare further".

STATEMENT from JINLEI CHEN, President of Midea Healthcare Division: "Esaote acquisition represents a strategic fit with Midea Healthcare. ESAOTE brings outstanding expertise, strong innovation capabilities, and a respected reputation. By combining its technology and vision with Midea Healthcare's technology and international resources, we believe we can further expand its global reach and contribute to the advancement of healthcare. We are excited to begin this new chapter together."

STATEMENT from ERIC WANG, Executive President of Midea Group: "We are delighted to welcome Esaote to Midea Group. This acquisition marks an important step in our healthcare strategy and reflects our long-term commitment to supporting innovative medical technologies with global potential. The combination of Esaote and Midea will result in a comprehensive and more diversified imaging offering, broadening customer choice and improving access to advanced diagnostic technologies in international markets".

About Esaote: Esaote is a leading Italian innovator in medical imaging. In fiscal year 2025, the Group reported revenues of EUR 267 millions, of which 70% in international markets. The company is among the top ten manufacturers of ultrasound and open and dedicated MRI world-wide and one of the leader in medical IT. The company has about 1,160 employees, 20% of which are engaged in R&D. a sector in which Esaote invests about 12% of its annual revenues. Through its subsidiaries and a widespread sales network, Esaote is present in over 100 countries worldwide. www.esaote.com

About Midea: Midea Group Co., Ltd., headquartered in Shunde, Foshan, Guangdong Province, is a global Chinese technology group founded in 1968 and active across seven business segments: smart home, industrial technology, building technology, robotics and automation, new energy, healthcare, and smart logistics. The Midea Group's global revenue in 2025 amounted to about USD 64.3 billion worldwide. The company is listed on the Shenzhen Stock Exchange (SZSE) and on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK). Midea ranks No.231 in the Fortune Global 500 ranking in 2026. In recent years, Midea has established Midea Healthcare Division, that focuses on intelligent medical imaging equipment and solutions.

© Copyright Esaote 2026

SOURCE Esaote S.p.A.

Share this article

Firm named a 100 Best Company and Global Talent and Inclusion Index Company and earns Pinnacle status in the U.S.

MENLO PARK, Calif., Oct. 9, 2026 /PRNewswire/ -- Protiviti, a global consulting firm, has been named to Seramount's 2026 100 Best Company and Global Talent and Inclusion Index lists. The firm also earned Pinnacle status, the highest recognition level, on Seramount's U.S. Talent and Inclusion Index.

Seramount evaluates participating organizations based on workforce data and workplace practices related to representation, recruitment, retention, advancement, benefits, leave policies, childcare support, mentorship, leadership accountability and flexibility.

"At Protiviti, we believe people thrive when they have opportunities to grow, build meaningful connections and know their contributions matter," said Susan Haseley, Protiviti's executive vice president, Global Corporate Responsibility & Inclusion. "These recognitions reflect the care our people show one another and the shared values they bring to life every day. They also reinforce our responsibility to continue strengthening a workplace culture where everyone feels respected, included and empowered to make a positive impact."

Protiviti earned the following recognitions:

- 100 Best Companies: Honors organizations that support the representation and advancement of women through benefits and practices such as paid parental and caregiver leave, childcare assistance, mental health resources and flexible scheduling.

- Global Talent and Inclusion Index: Recognizes organizations that advance women and other underrepresented groups, foster inclusive workplace cultures and hold leaders accountable for progress. Protiviti was recognized in 10 markets: Australia, Canada, France, Germany, Hong Kong/China, India, Italy, Japan, the Netherlands and the United Kingdom.

- U.S. Talent and Inclusion Index: Evaluates organizations in areas including workforce representation, recruitment, retention, advancement and workplace culture. Protiviti earned Pinnacle status, the index's highest recognition level.

Protiviti supports employees across career and life stages through flexible work practices and benefits that include gender-neutral paid parental leave, a phase-back program for returning parents, back-up dependent care, adoption assistance, a sabbatical program, well-being resources and access to an Employee Assistance Program.

The firm also emphasizes mentorship and career development. Every new hire is assigned an advisor to support their career journey, and employees can participate in Protiviti employee network groups, including groups for women at all career levels, new parents and women in technology. Reflecting its broader commitment to an inclusive workplace, Protiviti was also recognized by Disability:IN as a 2026 World's Top Disability Inclusive Business.

Learn more about Protiviti's workplace culture and commitment to inclusion.

About Protiviti

Protiviti is a global consulting firm that helps clients transform and protect their businesses and respond to planned and unexpected events. Through a network of more than 90 offices in over 25 countries, Protiviti and its independent and locally owned member firms deliver deep expertise and tailored capabilities across technology, artificial intelligence, data, operations, finance, legal, compliance, human resources, marketing, digital, risk and internal audit. This work helps organizations accelerate innovation, navigate risk and safeguard what matters most.

Named to the Fortune 100 Best Companies to Work For® list since 2015, Protiviti Inc. has served more than 80 percent of Fortune 100 companies and nearly 80 percent of Fortune 500 companies. The firm also works with government agencies and smaller, growing companies, including those preparing to go public. Protiviti Inc. is a wholly owned subsidiary of Robert Half, which is publicly traded on the New York Stock Exchange under the symbol RHI.

SOURCE Protiviti

Share this article

Best Adjustable Mattress (2026): Sleep Number Named a Top Choice for Personalized Adjustable Comfort by Better Business Advice

NEW YORK, Oct. 9, 2026 /PRNewswire/ -- Better Business Advice has recognized Sleep Number as a top choice for personalized adjustable comfort in its 2026 guide to the best adjustable mattresses. Every Sleep Number mattress allows sleepers to make the bed firmer or softer as their comfort needs change.

Best Adjustable Mattress

- Sleep Number - known for adjustable mattresses that let sleepers choose how firm or soft the bed feels, with options for added cushioning, cooling, temperature control, and smart features.

A mattress may feel comfortable during a short showroom visit but different after several nights at home. Sleeping position, physical activity, soreness, room temperature, and personal preferences can all affect how a bed feels over time.

Sleep Number mattresses address this challenge with adjustable air chambers. Sleepers can add air for a firmer feel or release air for a softer feel instead of remaining limited to the firmness selected at the time of purchase.

The current Sleep Number range includes seven mattresses in the ComfortMode, ComfortNext, and Climate collections. Adjustable firmness is included across the entire range. Differences in cushioning, pressure relief, cooling, temperature control, mattress height, and connected features help consumers choose the model that fits their needs.

Personalized Firmness Levels

Every Sleep Number mattress allows sleepers to adjust how firm or soft the bed feels. The firmness can be changed without adding a mattress topper, rearranging foam layers, or replacing the mattress.

This flexibility may be helpful because comfort preferences do not always stay the same. A setting that feels comfortable for back sleeping may not provide the same comfort after switching to side sleeping. Exercise, temporary soreness, pregnancy, injury, and weight changes may also affect how much cushioning or support feels right.

Sleep Number recommends making small adjustments and sleeping at a new setting for several nights before changing it again. This gives the body time to settle into the new firmness level.

Compatible mattresses also offer Responsive Air technology. The feature notices changes caused by movement, sleeping position, and temperature, then makes small adjustments to help maintain the selected firmness during the night. Sleepers can still make their own changes whenever they want the bed to feel noticeably firmer or softer.

The method used to control the mattress depends on the collection. ComfortMode mattresses use a compatible remote and do not require Wi-Fi or an app. Compatible ComfortNext and Climate mattresses can be controlled through the Sleep Number app. Remote availability depends on the selected mattress and setup.

Each Person Can Adjust Their Side of the Bed

Couples often prefer different levels of firmness. One person may want a softer surface, while the other may feel more comfortable with firmer support.

Queen-size and larger Sleep Number mattresses can give each person a separate firmness setting. Each sleeper can adjust their side of the bed without changing how the other side feels.

This can be useful when sleeping positions or comfort preferences differ. A side sleeper may prefer more cushioning around the shoulders and hips. A back or stomach sleeper may want a firmer surface. With separate settings, neither person has to settle for one firmness level across the entire mattress.

The separate air chambers may also reduce how much movement is felt across the bed when one person turns over or gets up. The amount of movement felt will still depend on the sleeper, mattress, and base, so the feature does not guarantee complete motion isolation.

Separate settings can remain useful even when both sleepers initially choose similar firmness levels. Temporary soreness, a change in physical activity, or a new sleeping position may cause one person to want a different feel later. Each side can be adjusted whenever those needs change.

Seven Mattresses Across Three Collections

The current Sleep Number portfolio includes seven models divided among the ComfortMode, ComfortNext, and Climate collections. Every model offers adjustable firmness, but the amount of cushioning, cooling, pressure relief, and temperature control varies.

ComfortMode includes 10-inch and 11-inch mattresses. Both combine adjustable firmness with supportive foam and built-in cooling materials. They use remote controls, making them suitable for consumers who want a more straightforward way to adjust the mattress without depending on an app.

ComfortNext includes 12-inch, 13-inch, and 14-inch mattresses. As the mattresses become taller, they provide more cushioning, pressure relief, cooling material, and airflow. Select ComfortNext models combine adjustable air support with foam and small coils to create a more cushioned, traditional mattress feel.

The Climate collection focuses on temperature control. ClimateCool can actively cool each side of the bed while also providing adjustable firmness and Responsive Air technology.

Climate360 can both cool and warm each side separately. This may be especially helpful for couples when one person tends to sleep hot and the other prefers a warmer bed.

Choosing an Adjustable Mattress for Long-Term Use

Choosing a Sleep Number mattress involves more than selecting a firmness level. Since every model offers adjustable firmness, consumers can compare the mattresses based on cushioning, pressure relief, cooling, temperature control, mattress height, and preferred controls.

ComfortMode mattresses may suit sleepers who want adjustable firmness with a simpler setup and a more direct, supportive feel. ComfortNext models provide deeper cushioning and more pressure relief, which may appeal to side sleepers or anyone who prefers a taller mattress.

Mattress height ranges from 10 to 14 inches across the collection. This can affect the overall height of the bed and the type of fitted sheets needed.

Temperature preferences are another consideration. Built-in cooling materials may be enough for sleepers who only become warm occasionally. ClimateCool provides active cooling for those who regularly sleep hot. Climate360 offers the widest range of temperature choices by allowing each side to be cooled or warmed separately.

The mattress also needs a firm, flat surface that can evenly support the adjustable air chambers. A traditional box spring does not provide the required support. Suitable options include a compatible Sleep Number base, an appropriate platform bed, or bed slats placed no more than two inches apart.

An adjustable mattress and an adjustable base perform different functions. The mattress changes how firm or soft the sleeping surface feels. An adjustable base changes the position of the bed by raising areas such as the head or feet. The two can be used together, but an adjustable base is not required to change the mattress firmness.

Sleep Number received recognition from Better Business Advice because adjustable firmness is available throughout the mattress range rather than being limited to one model. The right choice will depend on the amount of cushioning, pressure relief, temperature control, mattress height, and connected features each sleeper wants.

Read the full review at Better Business Advice.

About Sleep Number

Sleep Number® is the leader in personalized sleep wellness. With adjustable firmness, pressure-relieving support and temperature balancing comfort built into every mattress, Sleep Number beds adapt to customers' changing needs, night after night, year after year. Backed by almost 40 years of innovation, 1,000+ patents and patents pending, and billions of hours of sleep data, Sleep Number has helped more than 16 million people achieve their best sleep.

Sleep Number mattresses, bases, bedding, and furniture are available at its stores nationwide and at SleepNumber.com.

About Better Business Advice: Better Business Advice covers the news and strategies driving modern business success. The information provided by Better Business Advice does not, and is not intended to, constitute legal advice; instead, all information, content, and materials are for general informational purposes only. As an affiliate, Better Business Advice may earn commissions from services mentioned in the links provided.

SOURCE BetterBusinessAdvice.com

Share this article

India Mental Health Alliance (IMHA) champions lived experience as central to shaping mental healthcare practice, service design and policy

NEW DELHI, Oct. 9, 2026 /PRNewswire/ -- On the occasion of World Mental Health Day (10th October), the India Mental Health Alliance (IMHA), a cross-sectoral network of 400 organisations from 30 Indian states, reaffirms its commitment to recognising lived experience as expertise, ensuring that the voices of people and vulnerable communities who have experienced mental health challenges; are central to how care is designed and delivered.

IMHA was founded with the belief that mental health is a shared developmental priority for the nation, and building a strong system of care requires collective responsibility. Over the past two years, IMHA has engaged with 3,380 mental health professionals across 135+ cities, and mobilised its member organisations to build collective capacity, enable knowledge-sharing, and embed lived experience expertise in care design and practice.

"These lived experiences offer an important source of knowledge about what mental healthcare looks like in practice i.e. how people experience services, navigate systems and seek support within their social and cultural contexts across India. IMHA believes that bringing clinical expertise together with lived and practice-based knowledge, is essential to building a mental health ecosystem that is more equitable, contextual and responsive to people's diverse needs," said Dr. Kavita Arora, Child & Adolescent Psychiatrist and Founding Cohort Member of IMHA.

Towards this commitment IMHA is building a co-curated and collaborative Knowledge Hub to make knowledge accessible from diverse sources and modalities, for eg-practitioner insights, field lessons, clinical and lived experience expertise and academic research grounded in local contexts.

As part of its broader work to amplify and mainstream lived experience as expertise, IMHA proudly presents India's first anthology of lived-experience narratives by 11 women leaders from across sectors, 'Homecoming: Mental Health Journeys of Resilience, Healing & Wholeness'. This evocative book brings together first-person accounts of women in urban India navigating severe mental health conditions, including depression, complex PTSD, suicide loss, intergenerational trauma, anxiety and OCD. In sharing their journeys, they invite us to reflect on how families, communities, workplaces and healthcare professionals understand and respond to mental health conditions. Link to short film | Link to the book

About the India Mental Health Alliance (IMHA)

The India Mental Health Alliance (IMHA) is a Section 8 not-for-profit organisation launched in late 2023 as a partnership between Vasvi and Ashish Bharat Ram, Amaha Health and Children First. IMHA is a cross-sectoral national alliance working to strengthen India's mental health ecosystem by convening stakeholders, building capacities and catalysing collaboration at scale, with a member base of 400 organisations across 30 Indian states representing health, gender, livelihood, climate & education. It focuses on capacity-building for community organisations, healthcare and educational institutions, as well as individual mental health practitioners through multi-channel knowledge sharing and learning initiatives. Through its work, IMHA aims to mainstream mental health as a national development priority; improve the quality of care; embed Lived Experience Expertise (LEE) in care design and practice; and mobilise long-term, unrestricted capital for India's mental health ecosystem.

Share this article

- In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary endpoints

- Results support the potential of prifemilast to deliver greater efficacy than apremilast, with low rates of serious adverse events and discontinuations similar to apremilast

- In a second, placebo-controlled Phase 3 trial, prifemilast demonstrated superior efficacy to placebo with responses maintained through 52 weeks

- With more than 1,000 participants dosed, prifemilast has an extensive clinical safety database, including more than 250 participants treated for 52 weeks

- These positive results reinforce the potential of prifemilast to treat immune-mediated inflammatory diseases beyond psoriasis; cAMPfield is advancing prifemilast into global Phase 2 trials in ulcerative colitis and Crohn's disease

SAN DIEGO, Oct. 9, 2026 /PRNewswire/ -- cAMPfield Therapeutics, Inc. (cAMPfield), a clinical-stage biopharmaceutical company developing well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, today highlighted data from a head-to-head Phase 3 trial in which prifemilast, its once-daily, preferential PDE4B inhibitor, demonstrated superior efficacy versus apremilast in adults with moderate-to-severe plaque psoriasis. Results from the head-to-head trial, a second Phase 3 trial, and a Phase 2 dose-ranging trial, all sponsored and conducted in China by cAMPfield's partner, Newsoara Biopharma Co., Ltd. (Newsoara), were presented in two posters at the 2026 Fall Clinical Dermatology Conference in Las Vegas.

In the head-to-head Phase 3 trial, prifemilast 20 mg once daily achieved superiority over apremilast 30 mg twice daily on both co-primary endpoints at Week 16. It nearly doubled the proportion of patients achieving at least a 75% improvement in Psoriasis Area and Severity Index (PASI 75) (64.6% vs. 35.3%) and the proportion of patients achieving clear or almost clear skin (sPGA 0/1, 55.6% vs. 31.3%; both P0.0001). Rates of serious adverse events (4.0% vs. 2.5%) and discontinuations due to adverse events (2.0% vs. 1.5%) were low and similar between treatment arms.1 In a second, placebo-controlled Phase 3 trial, responses were seen as early as Week 2 and maintained through 52 weeks.2 Discontinuations due to adverse events during the 16-week treatment period were similar with prifemilast and placebo (1.7%–1.8% vs. 1.8%).2

"Outperforming apremilast head-to-head is a high bar, and prifemilast cleared it decisively on both co-primary endpoints, demonstrating its potential to be a best-in-class PDE4 inhibitor," said Bill Gerhart, Chief Executive Officer at cAMPfield. "We are grateful to Newsoara and to the investigators and patients who made these trials possible, and we look forward to building on these results for patients living with IBD."

Plaque psoriasis (PsO) and inflammatory bowel disease (IBD) are immune-mediated inflammatory diseases that share overlapping inflammatory pathways, cytokine networks, and genetic risk factors.3 PDE4 inhibition has also shown activity in ulcerative colitis. In a Phase 2 trial in patients with ulcerative colitis, apremilast did not meet its primary endpoint at 40 mg twice daily, but at 30 mg twice daily (the dose used as the comparator in the PsO head-to-head trial), 31.6% of patients achieved clinical remission at Week 12 versus 12.1% on placebo.4 These results, together with clinical experience spanning more than 1,000 trial participants in the United States and China, including more than 250 participants treated for 52 weeks,5 support cAMPfield's advancement of prifemilast into global Phase 2 trials in ulcerative colitis and Crohn's disease.

"For more than a decade, the promise of PDE4 inhibition in IBD has been held back by the limitations of earlier-generation molecules," said Graham Heap, MD, PhD, President, R&D at cAMPfield. "The data presented at the conference suggest that prifemilast has the potential to be a highly effective PDE4 inhibitor, delivering meaningfully greater efficacy than the standard of the class with once-daily dosing. These results give us even greater confidence as we advance prifemilast into global Phase 2 trials in ulcerative colitis and Crohn's disease."

About the Prifemilast Psoriasis Clinical Trials

The prifemilast psoriasis program includes three randomized, double-blind, multicenter trials sponsored and conducted in China by Newsoara to evaluate the efficacy, safety and tolerability of prifemilast in adults with moderate-to-severe plaque psoriasis.

The head-to-head Phase 3 trial (NCT07712731) randomized 607 participants 2:1 to prifemilast 20 mg once daily or apremilast 30 mg twice daily for 16 weeks; apremilast was titrated in line with its US prescribing information, while prifemilast required no titration.1,6 The co-primary endpoints were the proportion of patients achieving PASI 75 and sPGA 0/1 at Week 16.

The placebo-controlled Phase 3 trial (NCT07712705) randomized more than 500 participants to prifemilast 10 mg, prifemilast 20 mg, or placebo once daily for 16 weeks, followed by a 36-week extension in which all participants received prifemilast. The Phase 2 dose-ranging trial (NCT07707141) randomized 123 participants to prifemilast 6 mg, 10 mg or 20 mg or placebo once daily for 12 weeks and showed dose-dependent improvements, with 67.7% of patients on 20 mg (n=31) achieving clear or almost clear skin at Week 12 compared with 6.7% on placebo.2 The primary endpoint of both placebo-controlled trials was PASI 75 response.

Poster Presentations

Two posters were presented at the 26th Annual Fall Clinical Dermatology Conference, being held October 8–11, 2026, in Las Vegas, and are available on the cAMPfield website at https://campfieldtx.com. The abstracts and posters are expected to be published in the Dermatology Online Journal.

- Poster 1: Prifemilast, an Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor, Demonstrates Rapid and Durable Efficacy With a Favorable Tolerability and Safety Profile in Moderate to Severe Plaque Psoriasis: Results From Phase 2 and 3 Trials

- Poster 2: Superior Efficacy of the Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor Prifemilast Versus Apremilast in Moderate to Severe Plaque Psoriasis: Top-Line Results of a Head-to-Head Phase 3 Trial

About Prifemilast

Prifemilast is an investigational, once-daily, preferential PDE4B inhibitor that has been studied in more than 1,000 participants in the United States and China to date, including more than 250 participants treated for 52 weeks.5 Prifemilast targets PDE4B, the isoform most closely associated with anti-inflammatory activity, while minimizing inhibition of PDE4D, an isoform associated with dose-limiting adverse effects. Its structure limits central nervous system penetration and slows absorption, and its extended half-life supports once-daily dosing.7 Prifemilast has demonstrated superior efficacy to apremilast in a head-to-head Phase 3 trial and positive results in a placebo-controlled Phase 3 trial in plaque psoriasis. Across these trials, its safety profile was consistent with the PDE4 inhibitor class, with rates of discontinuation due to adverse events comparable to placebo and similar to apremilast. Prifemilast is an investigational drug and has not been approved by any regulatory authority for any indication.

About Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic immune-mediated inflammatory disease that affects more than 6.8 million people worldwide8 and remains an area of substantial unmet medical need. Despite significant advances in treatment, many patients fail to achieve durable remission or lose response over time, resulting in frequent treatment switching. While biologic therapies have transformed outcomes for many patients, there remains a need for additional effective, well-tolerated treatment options. Convenient oral therapies are an important part of the treatment landscape, yet currently approved oral agents for IBD are limited by tolerability, safety concerns and/or modest efficacy.9

About cAMPfield Therapeutics

cAMPfield Therapeutics is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, including inflammatory bowel disease. cAMPfield was founded by Mountainfield Venture Partners in partnership with executives who played key roles in the development and/or commercialization of Entyvio®, Humira®, Otezla®, and Zeposia®. cAMPfield holds exclusive global development and commercialization rights to prifemilast for all indications outside Greater China through a license agreement with Newsoara Biopharma Co., Ltd.

The company is headquartered in San Diego, California. For more information, visit www.campfieldtx.com.

About Newsoara Biopharma Co., Ltd.

Newsoara Biopharma Co., Ltd. (Newsoara) is an innovation-driven biopharmaceutical company founded in 2018 and headquartered in Shanghai, China. Newsoara is focused on the discovery and development of differentiated innovative therapies for autoimmune diseases, oncology and metabolic disorders. Newsoara has built an integrated drug development platform spanning drug discovery, translational research, clinical development and regulatory affairs, with a pipeline of 12 innovative drug candidates.

Newsoara has led the development of prifemilast (HY1999) in China, including preclinical development, CMC, Phase 1, Phase 2 and two Phase 3 clinical trials in moderate-to-severe plaque psoriasis. Newsoara plans to submit a New Drug Application (NDA) for prifemilast in plaque psoriasis in China by the end of 2026. Newsoara has granted cAMPfield Therapeutics exclusive development and commercialization rights to prifemilast for all indications outside Greater China, while retaining rights in Greater China.

HELLERUP, Denmark, Oct. 9, 2026 /PRNewswire/ -- TORM plc (NASDAQ: TRMD) (NASDAQ: TRMD A) announces that, following Oaktree Capital Management and its affiliates no longer holding an ownership interest in TORM, Christopher Boehringer has stepped down from TORM's Board of Directors with immediate effect.

Christopher Boehringer joined the Board in 2015 and has played an important role in supporting TORM throughout a period of significant transformation and growth. The Board wishes to express its sincere appreciation for his longstanding commitment, strategic insight, and valuable contributions to the Company.

Christopher Boehringer commented:

"It has been a great privilege serving TORM through numerous transformative events and business cycles. The success of the One TORM platform is a direct result of the enormous contributions from our associates, our management, and our Board, all working in concert to deliver safety, excellence, and value. I am honored to have worked with such an extraordinary team. I am grateful for their trust and support, and I am confident in the Company's future success."

Simon Mackenzie Smith, Chair of TORM, stated:

"On behalf of the Board, I would like to express our sincere gratitude to Chris for his dedicated service and invaluable contributions over the past eleven years. Chris has been a trusted adviser and strong supporter of TORM through some of the most important milestones in the Company's history, including developing and strengthening the One TORM platform. His deep industry knowledge, sound judgment and unwavering commitment have helped shape TORM into the company it is today. We thank Chris for his friendship, counsel and leadership, and we wish him every success in the future."

Following this change, the Board of Directors of TORM plc comprises Simon Mackenzie Smith (Chair), Annette Malm Justad, Göran Trapp, Jann Brown, and Jacob Meldgaard.

Mikael Bo Larsen, Head of Investor Relations

Tel.: +45 5143 8002

About TORM

TORM is one of the world's leading carriers of refined oil products. TORM operates a fleet of product tanker vessels with a strong commitment to safety. environmental responsibility and customer service. TORM was founded in 1889 and conducts business worldwide. TORM's shares are listed on Nasdaq in Copenhagen and on Nasdaq in New York (Nasdaq: TRMD A) (Nasdaq: TRMD) (ISIN: GB00BZ3CNK81). For further information, please visit www.torm.com.

Safe Harbor Statement as to the Future

Matters discussed in this release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. Words such as, but not limited to, "expects," "anticipates," "intends," "plans," "believes," "estimates," "targets," "projects," "forecasts," "potential," "continue," "possible," "likely," "may," "could," "should" and similar expressions or phrases may identify forward-looking statements.

The forward-looking statements in this release are based upon various assumptions, many of which are, in turn, based upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, the Company cannot guarantee that it will achieve or accomplish these expectations, beliefs, or projections.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, our future operating or financial results; changes in governmental rules and regulations or actions taken by regulatory authorities; inflationary pressure and central bank policies intended to combat overall inflation and rising interest rates and foreign exchange rates; general domestic and international political conditions or events, including "trade wars" and the war between Russia and Ukraine, the developments in the Middle East, including the war in Israel and the Gaza Strip, and the conflict regarding the Houthis' attacks in the Red Sea; international sanctions against Russian oil and oil products; changes in economic and competitive conditions affecting our business, including market fluctuations in charter rates and charterers' abilities to perform under existing time charters; changes in the supply and demand for vessels comparable to ours and the number of newbuildings under construction; the highly cyclical nature of the industry that we operate in; the loss of a large customer or significant business relationship; changes in worldwide oil production and consumption and storage; risks associated with any future vessel construction; our expectations regarding the availability of vessel acquisitions and our ability to complete acquisition transactions planned; availability of skilled crew members other employees and the related labor costs; work stoppages or other labor disruptions by our employees or the employees of other companies in related industries; effects of new products and new technology in our industry; new environmental regulations and restrictions; the impact of an interruption in or failure of our information technology and communications systems, including the impact of cyber-attacks, upon our ability to operate; potential conflicts of interest involving members of our Board of Directors and Senior Management; the failure of counterparties to fully perform their contracts with us; changes in credit risk with respect to our counterparties on contracts; adequacy of insurance coverage; our ability to obtain indemnities from customers; changes in laws, treaties or regulations; our incorporation under the laws of England and Wales and the different rights to relief that may be available compared to other countries, including the United States; government requisition of our vessels during a period of war or emergency; the arrest of our vessels by maritime claimants; any further changes in U.S. trade policy that could trigger retaliatory actions by the affected countries; the impact of the U.S. presidential and congressional election results affecting the economy, future government laws and regulations and trade policy matters, such as the imposition of tariffs and other import restrictions; potential disruption of shipping routes due to accidents, climate-related incidents, adverse weather and natural disasters, environmental factors, political events, public health threats, acts by terrorists or acts of piracy on ocean-going vessels; damage to storage and receiving facilities; potential liability from future litigation and potential costs due to environmental damage and vessel collisions; and the length and number of off-hire periods and dependence on third-party managers.

In the light of these risks and uncertainties, undue reliance should not be placed on forward-looking statements contained in this release because they are statements about events that are not certain to occur as described or at all. These forward-looking statements are not guarantees of our future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements.

Except to the extent required by applicable law or regulation, the Company undertakes no obligation to release publicly any revisions or updates to these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Please see TORM's filings with the U.S. Securities and Exchange Commission for a more complete discussion of certain of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/torm-plc/r/torm-plc-announces-change-to-the-board,c4406587

The following files are available for download:

SOURCE Torm PLC

Share this article